Treatment of Inflammatory Bowel Disease With 2-Methylene-19-Nor-Vitamin D Compounds

Abstract

A method of preventing and/or treating inflammatory bowel disease, particularly ulcerative colitis and Crohn's disease, is disclosed. The method involves administering a 2-methylene-19-nor-vitamin D compound in an amount effective to treat the disease. The administration of a 2-methylene-19-nor-vitamin D compound also prevents the development of or delays the onset of inflammatory bowel disease in susceptible individuals. The preferred compounds are 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D 3 .

1 . (canceled) 
   
   
       2 . (canceled) 
   
   
       3 . (canceled) 
   
   
       4 . (canceled) 
   
   
       5 . (canceled) 
   
   
       6 . (canceled) 
   
   
       7 . (canceled) 
   
   
       8 . (canceled) 
   
   
       9 . (canceled) 
   
   
       10 . (canceled) 
   
   
       11 . (canceled) 
   
   
       12 . (canceled) 
   
   
       13 . (canceled) 
   
   
       14 . (canceled) 
   
   
       15 . (canceled) 
   
   
       16 . (canceled) 
   
   
       17 . (canceled) 
   
   
       18 . (canceled) 
   
   
       19 . A method of treating Crohn's disease comprising administering to a patient with Crohn's disease 2-methylene-19-nor-20(S)-1α,25-dihydroxy vitamin D 3  having the formula: 
     
       
         
         
             
             
         
       
     
     as the only active ingredient. 
   
   
       20 . The method of  claim 19  wherein the compound is administered orally. 
   
   
       21 . The method of  claim 19  wherein the compound is administered parenterally. 
   
   
       22 . The method of  claim 19  wherein the compound is administered transdermally. 
   
   
       23 . The method of  claim 19  wherein the compound is administered in a dosage of from 0.01 μg to 10 mg per day per 160 pound person.